
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Drug Discovery Pipeline Knowledge Base</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header>
    <h1>Drug Discovery Pipeline Knowledge Base</h1>
    <p>Comprehensive guide to the stages of drug development</p>
  </header>
  <nav>
    <ul>
      <li><a href="target_identification.html">Target Identification</a></li>
      <li><a href="hit_discovery.html">Hit Discovery</a></li>
      <li><a href="lead_optimization.html">Lead Optimization</a></li>
      <li><a href="preclinical.html">Preclinical Development</a></li>
      <li><a href="clinical.html">Clinical Trials</a></li>
      <li><a href="regulatory.html">Regulatory Approval</a></li>
      <li><a href="post_marketing.html">Post-Marketing Surveillance</a></li>
    </ul>
  </nav>

  <main>
    <section>


<h1>Disease Association: Molecular and Translational Insights</h1>

  <div class="section">
    <h2>1. Molecular Basis of Disease Association</h2>
    <ul>
      <li><strong>Genetic Variants:</strong> Loss-of-function (e.g., CFTR in cystic fibrosis), gain-of-function (e.g., BRAF V600E in melanoma), and CNVs affecting dosage-sensitive genes.</li>
      <li><strong>Regulatory Elements:</strong> Promoter/enhancer mutations and non-coding RNAs (miRNAs, lncRNAs) modulate gene expression in disease.</li>
      <li><strong>Epigenetic Modifications:</strong> Aberrant methylation or histone acetylation can silence tumor suppressors or activate oncogenes.</li>
    </ul>
  </div>

  <div class="section">
    <h2>2. Computational and Systems-Level Approaches</h2>
    <ul>
      <li><strong>PPI Networks:</strong> Identify hub proteins central to disease phenotypes.</li>
      <li><strong>Gene Co-expression Networks:</strong> Reveal dysregulated modules in disease states.</li>
      <li><strong>Pathway Enrichment:</strong> Map differentially expressed genes to biological pathways (e.g., KEGG, Reactome).</li>
      <li><strong>AI Models:</strong> Use machine learning and graph neural networks to uncover hidden associations.</li>
    </ul>
  </div>

  <div class="section">
    <h2>3. Experimental Validation Techniques</h2>
    <table>
      <thead>
        <tr>
          <th>Technique</th>
          <th>Purpose</th>
          <th>Example</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td>CRISPR Screens</td>
          <td>Functional knockout to assess phenotypic impact</td>
          <td>Essential gene identification in cancer</td>
        </tr>
        <tr>
          <td>RNAi Knockdown</td>
          <td>Transient silencing to test gene relevance</td>
          <td>Neurodegenerative disease models</td>
        </tr>
        <tr>
          <td>Chemical Probes</td>
          <td>Modulate target activity to confirm involvement</td>
          <td>Kinase validation in inflammation</td>
        </tr>
        <tr>
          <td>Organoids & iPSCs</td>
          <td>Patient-derived models for personalized validation</td>
          <td>Cystic fibrosis lung organoids</td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="section">
    <h2>4. Clinical Translation and Biomarker Integration</h2>
    <ul>
      <li><strong>Predictive Biomarkers:</strong> Indicate likely response to therapy (e.g., EGFR mutations).</li>
      <li><strong>Prognostic Biomarkers:</strong> Reflect disease outcome (e.g., p53 status).</li>
      <li><strong>Pharmacodynamic Biomarkers:</strong> Monitor biological response (e.g., cytokine levels).</li>
      <li><strong>Companion Diagnostics:</strong> Co-developed with therapies (e.g., HER2 testing for trastuzumab).</li>
      <li><strong>Real-World Evidence:</strong> EHRs and post-marketing data reveal long-term associations.</li>
    </ul>
  </div>

  <div class="section">
    <h2>5. Feedback Loop: From Clinic to Bench</h2>
    <ul>
      <li><strong>Treatment Resistance:</strong> Reveals new associations (e.g., secondary kinase mutations).</li>
      <li><strong>Longitudinal Omics:</strong> Tracks disease evolution and dynamic associations.</li>
      <li><strong>Adaptive Trials:</strong> Incorporate emerging biomarkers to refine hypotheses.</li>
    </ul>
  


    </section>
  </main>
  <footer>
    <p>&copy; 2025 Drug Discovery Knowledge Base</p>
  </footer>
</body>
</html>
